Effects of Bisphosphonate Administration on the Bone Mass in Immune Thrombocytopenic Purpura Patients Under Treatment With Steroids

Abstract

Immune thrombocytopenic purpura (ITP) is an acquired hemorrhage condition involving accelerated platelet consumption caused by antiplatelet autoantibodies. Although various therapeutic strategies are used to treat patients with ITP, the standard treatment method is steroid therapy. The most important problem with steroid administration may be a prolonged use tendency in many cases, because there are many refractory chronic patients. To elucidate the effects of glucocorticoid on bone mineral density (BMD) in patients with ITP, we retrospectively evaluated the relationship between BMD and the total dose of glucocorticoid or the mean daily dose given. We observed decreased BMD in 66.7% of the patients with ITP to whom glucocorticoid was given, although normal bone BMD was observed in 28.6% of patients with ITP treated without steroids. The mean level of BMD was markedly decreased in steroid-treated patients compared with nonsteroid-treated patients (P < .01). The relationship between BMD and the total dose of glucocorticoid (P = .023) or the mean daily dose revealed a negative correlation (P = .022). Administration of bisphosphonate revealed a significant increase in bone mass in patients at 6 and 12 months after the start of bisphosphonate treatment, despite the aggravation of thrombocytopenia. In conclusion, glucocorticoid-induced osteoporosis was observed in patients with ITP, similar to situation seen in patients with other diseases. Bisphosphonate may be an effective agent for the prevention and treatment of glucocorticoid-induced osteoporosis in patients with ITP scheduled to receive long-term steroid treatment.

Keywords

immune thrombocytopenic purpura bisphosphonate steroid bone mass quality of life

References

Cines DB , Blanchette VS Immune thrombocytopenic purpura. N Engl J Med. 2002;346(13):995-1008.

George JN Management of patients with refractory immune thrombocytopenic purpura . J Thromb Haemost. 2006;4(8): 1664-1672.

Bussel JB Treatment of immune thrombocytopenic purpura in adults. Semin Hematol. 2006;43(3 suppl 5):S3-S10.

Psaila B. , Bussel JB Refractory immune thrombocytopenic purpura: current strategies for investigation and management. Br J Haematol. 2008;143(1):16-26.

Stasi R. , Evangelista ML , Stipa E. , Buccisano F. , Venditti A. , Amadori S. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost. 2008;99(1):4-13.

Frederiksen H. , Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increase with age. Blood. 1999;94(3): 909-913.

Van Staa TP , Leufkens HG , Abenhaim L. , Zhang B. , Cooper C. Use of oral corticpsteroids and risk of fracture. J Bone Miner Res. 2000;15(6):993-1000.

Clowes JA , Peel N. , Eastell R. Glucocorticoid-induced osteoporosis. Curr Opin Rheumatol . 2001;13(4):326-332.

Cram P. , Schlechte J. , Christensen A. A randomized trial to assess the impact of direct reporting of DXA scan results to patients on quality of osteoporosis care. J Clin Densitom . 2006;9(4):393-398.

10.

Sosa M. , Hernandez D. , Segarra MC , Gómez A. , de la Peña E. , Betancor P. Effect of two forms of alendronate administration upon bone mass after two years of treatment. J Clin Densitom. 2002 ;5(1):27-34.

11.

Sawka AM , Thabane L. , Papaioannou A. , Gafni A. , Hanley DA , Adachi JD A systemic review of the effect of alendronate on bone mineral density in men. J Clin Densitom. 2005;8(1):7-13.

12.

Bruder JM , Ma JZ , Wing N. , Basler J. , Katselnik D. Effects of alendronate on bone mineral density in men with prostate cancer treated with androgen deprivation therapy. J Clin Densitom . 2006;9(4):431-437.

13.

Patschan D. , Loddenkemper K. , Buttgereit F. Molecular mechanisms of glucocorticoid-induced osteoporosis. Bone. 2001;29(6): 498-505.

14.

American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis; 2001 update. Arthritis Rheum. 2001;44(7): 1496-1503.

15.

Eastell R. , Reid DM , Compston J. , et al. A UK consensus group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med. 1998 ;244(4):271-292.

16.

Adachi JD , Olszynski WP , Hanley DA , et al. Management of corticosteroid-induced osteoporosis. Semin Arthritis Rheum. 2000;29(4):228-251.

17.

Brown JP , Josse RG 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ. 2001;167(10 suppl):S1-S34.

18.

Reid IR Glucocorticoid-induced osteoporosis: assessment and treatment. J Clin Densitom. 1998;1(1):65-73.

19.

Hanley DA , Ioannidis G. , Adachi JD Etrironate therapy in the treatment and prevention of osteoporosis . J Clin Densitom. 2000;3(1):79-95.

20.

Cheng A. , Mavrokokki A. , Carter G. , et al. The dental implications of bisphosphonates and bone disease . Aust Dent J. 2005; 50(4 suppl 2):S4-S13.

21.

Woo SB , Hellstein JW , Kalmar JR Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws . Ann Intern Med. 2006;144(10):753-761.

22.

Font RG , Garcia MLM , Martinez JMO. Osteochemonecrosis of the jaws due to bisphosphonate treatments: update . Med Oral Patol Oral Cir Bucal. 2008;13(5):E318-E324.